This paper reported beta-blocker use in 21 STEMI patients over four years. The patients were between 50 - 65 years of age presenting with anterior, lateral, and inferior STEMI (ST-Elevation Myocardial Infarction). Seven of the patients were female, and 14 were male. They presented to an emergency room of a rural hospital that did not provide emergency percutaneous coronary angioplasty/stenting (PTCA/stenting). The hospital is about 70 minutes from a facility that provided PTCA/ stenting—all the patients presented with typical angina chest pain with ST elevation. They are hemodynamic stable. Most patients received Lopressor 35 mg IVP, with one receiving 115 mg in a 5 mg increment. They were chest pain-free and hemodynamically before leaving the ER for the transfer for PTCA/stent. The results demonstrated that beta-blockers are effective in relieving pain in STEMI patients. Further study is needed to determine its efficacy, safety, and how to use it.
References
[1]
Virani, S.S., Alonso, A., Benjamin, E.J., Bittencourt, M.S., Callaway, C.W., Carson, A.P., etal. (2020) Heart Disease and Stroke Statistics—2020 Update: A Report from the American Heart Association. Circulation, 141, e139-e596. https://doi.org/10.1161/CIR.0000000000000757
[2]
Atherosclerosis Risk in Communities (ARIC) Study. Community Surveillance Component, 2005-2014. https://sites.cscc.unc.edu/aric/
[3]
Antman, E.M., Anbe, D.T., Armstrong, P.W., Bates, E.R., Green, L.A., Hand, M., etal. (2004) ACC/AHA Guidelines for the Management of Patients with St-Elevation Myocardial Infarction—Executive Summary. Circulation, 110, 588-636. https://doi.org/10.1161/01.cir.0000134791.68010.fa
[4]
Keeley, E.C. and Grines, C.L. (2004) Primary Percutaneous Coronary Intervention for Every Patient with St-Segment Elevation Myocardial Infarction: What Stands in the Way? AnnalsofInternalMedicine, 141, 298-304. https://doi.org/10.7326/0003-4819-141-4-200408170-00010
[5]
Concannon, T.W., Nelson, J., Kent, D.M. and Griffith, J.L. (2013) Evidence of Systematic Duplication by New Percutaneous Coronary Intervention Programs. Circulation: CardiovascularQualityandOutcomes, 6, 400-408. https://doi.org/10.1161/circoutcomes.111.000019
[6]
Wang, H.E. and Yealy, D.M. (2012) Distribution of Specialized Care Centers in the United States. AnnalsofEmergencyMedicine, 60, 632-637.E7. https://doi.org/10.1016/j.annemergmed.2012.02.020
[7]
The Norwegian Multicenter Study Group (1981) Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. NewEnglandJournalofMedicine, 304, 801-807. https://doi.org/10.1056/nejm198104023041401
[8]
Madhavan, M., Borlaug, B.A., Lerman, A., Rihal, C.S. and Prasad, A. (2009) Stress Hormone and Circulating Biomarker Profile of Apical Ballooning Syndrome (Takotsubo Cardiomyopathy): Insights into the Clinical Significance of B-Type Natriuretic Peptide and Troponin Levels. Heart, 95, 1436-1441. https://doi.org/10.1136/hrt.2009.170399
[9]
Albert, S. and Gert, R. (1990) The Role of Catecholamines in Ischemia. Journal of Cardiovascular Pharmacology, 16, S105-S112. https://doi.org/10.1097/00005344-199006165-00019
[10]
Halkin, A., Grines, C.L., Cox, D.A., Garcia, E., Mehran, R., Tcheng, J.E., etal. (2004) Impact of Intravenous Beta-Blockade before Primary Angioplasty on Survival in Patients Undergoing Mechanical Reperfusion Therapy for Acute Myocardial Infarction. JournaloftheAmericanCollegeofCardiology, 43, 1780-1787. https://doi.org/10.1016/j.jacc.2003.10.068
[11]
Akashi, Y.J., Nef, H.M. and Lyon, A.R. (2015) Epidemiology and Pathophysiology of Takotsubo Syndrome. Nature Reviews Cardiology, 12, 387-397. https://doi.org/10.1038/nrcardio.2015.39
[12]
Parkkonen, O., Allonen, J., Vaara, S., Viitasalo, M., Nieminen, M.S. and Sinisalo, J. (2014) Differences in St-Elevation and T-Wave Amplitudes Do Not Reliably Differentiate Takotsubo Cardiomyopathy from Acute Anterior Myocardial Infarction. JournalofElectrocardiology, 47, 692-699. https://doi.org/10.1016/j.jelectrocard.2014.06.006
[13]
The TIMI Study Group (1989) Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction. NewEnglandJournalofMedicine, 320, 618-627. https://doi.org/10.1056/nejm198903093201002
